Danaher Corporation has announced today the completion of the sale of some of its businesses to Sartorius AG for a consideration of $825 million. The sale was a requirement in order to obtain regulatory approval for Danaher’s acquisition of the GE Biopharma business, now called Cytiva. The sale included its label-free biomolecular characterization, chromatography hardware […]
Danaher Corporation (NYSE: DHR) today announced that the Company’s Board of Directors has implemented its previously disclosed succession plan and will appoint Thomas P. Joyce, Jr. as President and Chief Executive Officer and a member of the Board of Directors, effective September 9, 2014. Mr. Joyce’s predecessor, H. Lawrence Culp, Jr., will transition to a senior advisory role. […]
Danaher Corp. has today reported record results both for the final quarter and for the full year. H. Lawrence Culp, Jr., President and Chief Executive Officer, stated, “Our strong finish in 2013 contributed to a solid year for Danaher overall. Our team’s application of the Danaher Business System drove relative top line outperformance, solid […]
Danaher Corporation today announced financial results for the second quarter of 2013. Revenues for the quarter were 4% up on the same period last year reaching $4.7 billion. H. Lawrence Culp, Jr., President and CEO said that sales had been somewhat higher than expected. More…
Danaher Corporation (NYSE: DHR) announced results for the fourth quarter and full year 2012. All financial metrics in this release reflect only the Company’s continuing operations unless otherwise noted. Net earnings for the quarter ended December 31, 2012 were $630.4 million, or $0.89 per share on a diluted basis, a 12.5% increase over diluted net earnings per share of $0.79 for the fourth […]